AXPAXLI Could Turn Ocular Therapeutix Into a Retina Franchise - Actionable Long Trade
Ocular Therapeutix's AXPAXLI (OTX-TKI) presents a credible path from clinical success to durable commercial advantage in wet AMD. With Phase 3 data showing sustained durability, a $666.7M cash cushion and a $1.9B market cap, the stock offers asymmetric upside versus clear binary risks. This trade idea lays out entry, stop and target, catalysts to w…